Ichnos Glenmark presents data from Phase 1 study of ISB 2001 in multiple myeloma
In a presentation at the 66th American Society of Hematology Annual Meeting, Ichnos Glenmark Innovation (IGI) unveiled promising results from its Phase 1 clinical trial ... Read More
Glenmark Pharmaceuticals expands ophthalmic portfolio with new Travoprost Ophthalmic Solution
In a significant move to bolster its position in the United States generics market, Glenmark Pharmaceuticals Inc., USA has launched Travoprost Ophthalmic Solution USP, 0.004% ... Read More
Ichnos Glenmark Innovation’s phase 1 study of trispecific antibody shows strong results in myeloma treatment
Ichnos Glenmark Innovation (IGI), a collaboration between Glenmark Pharmaceuticals Limited and Ichnos Sciences Inc., has unveiled promising results from its Phase 1 clinical trial involving ... Read More
Glenmark’s stunning Q1 performance: How the pharma powerhouse is dominating global markets
Glenmark Pharmaceuticals Limited (Glenmark) has announced impressive financial results for the first quarter of FY 2024-25, marked by a 6.9% increase in consolidated revenue and ... Read More
Glenmark Pharmaceuticals reports Q4 FY2023-24 revenue of Rs 30.63bn
Glenmark Pharmaceuticals Limited, a research-led, global pharmaceutical company, today released its financial results for the fourth quarter ending March 31, 2024, showcasing a solid performance ... Read More
Glenmark Pharmaceuticals to tap into $290m market with FDA approval for eye treatment solution
In a significant development for Glenmark Pharmaceuticals Ltd., the company has received final approval from the United States Food & Drug Administration (U.S. FDA) for ... Read More
Glenmark Pharmaceuticals secures FDA approval for generic version of Otezla Tablets
Glenmark Pharmaceuticals Ltd. has successfully secured the final approval from the United States Food & Drug Administration (U.S. FDA) for its Apremilast Tablets in 10 ... Read More
Ichnos Sciences strikes exclusive global deal with Astria Therapeutics for OX40 antibody portfolio
Ichnos Sciences, a prominent clinical-stage biotechnology firm specializing in pioneering multispecific antibodies for oncology and under the ownership of Glenmark Pharmaceuticals, has announced a momentous ... Read More
Glenmark Pharma to sell 75% stake in Glenmark Life Sciences to Nirma Limited
Glenmark Pharmaceuticals (Glenmark Pharma), a research-led global pharmaceutical player, has inked a deal with Nirma Limited to divest a substantial 75% stake in its offshoot, ... Read More
Glenmark Pharmaceuticals gets FDA approval for generic Protopic Ointment
Glenmark Pharmaceuticals Ltd., a global leader in pharmaceutical research, has secured the final nod from the U.S. Food & Drug Administration (U.S. FDA) for its ... Read More